PCN66 A COST-UTILITY ANALYSIS OF NIVOLUMAB IN THE ADJUVANT TREATMENT OF MELANOMA IN FRANCE
Abstract
Authors
S. Teitsson B. Bregman F.E. Cotte M. Augusto A. Amadi A. Moshyk S. Roze A.F. Gaudin
S. Teitsson B. Bregman F.E. Cotte M. Augusto A. Amadi A. Moshyk S. Roze A.F. Gaudin
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now